Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biopharma Goes 3 For 3 In Presidential Debates

Executive Summary

The Presidential debates are over, and the biopharmaceutical industry has to be counted among the winners, simply because there was no substantive discussion of high drug prices as an issue. That may not mean much come 2017 – but at least the industry’s reputation hasn’t been further damaged during the highest profile phase of the national campaign.

Advertisement

Related Content

Clinton Transition Co-Chair Tanden Offers Themes For A Drug Pricing Bill In 2017
Drug Prices Enter Presidential Debate – Not That Anyone Noticed
Big Pharma’s Big Debate Win

Topics

Advertisement
UsernamePublicRestriction

Register